Jazz Pharmaceuticals has filed a patent for using cannabidiol (CBD) to treat seizures linked to herpes simplex virus. The patent claims a CBD preparation specifically for this purpose, with recommended doses ranging from 5 mg/kg/day to 50 mg/kg/day. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jazz Pharmaceuticals Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240033272A1) discloses a cannabidiol (CBD) preparation specifically designed for treating seizures associated with herpes simplex virus. The preparation is formulated to target various types of seizures, including tonic, tonic-clonic, atonic, myoclonic, absence, and focal seizures with impairment. The CBD preparation contains a high concentration of CBD (>95% w/w) and minimal tetrahydrocannabinol (THC) content (<0.15% w/w), ensuring the therapeutic benefits of CBD without the psychoactive effects of THC. Additionally, the preparation may include other cannabinoids such as CBD-C1, CBDV, and CBD-C4 in specific proportions, along with a combination of anti-epileptic drugs for enhanced efficacy.

Furthermore, the patent application outlines different administration methods for the CBD preparation, including isolated CBD from cannabis plant material or synthetic CBD preparations. The recommended dosage of CBD for treating seizures associated with herpes simplex virus ranges from 5 mg/kg/day to 50 mg/kg/day, depending on the severity of the condition. The patent also covers a method for treating these seizures by administering the CBD preparation to individuals in need of such treatment. Overall, the patent application highlights the potential of CBD in managing seizures associated with herpes simplex virus and provides detailed formulations and dosing guidelines for effective treatment.

To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies